Literature DB >> 20387478

[To investigate pathogen of hand, foot and mouth disease in Shenzhen in 2008].

Hong-mei Zhang1, Cheng-rong Li, Yong-jun Liu, Wei-long Liu, Dan Fu, Liu-mei Xu, Jing-jing Xie, Yan Tan, Hui Wang, Xin-chun Chen, Bo-ping Zhou.   

Abstract

OBJECTIVE: To investigate EV71 and CA16 pathogen of HFMD in Shenzhen in 2008, and to provide the evidence for the prevention and treatment HFMD.
METHOD: Using RT-PCR technology to detect the EV71 and CoxA16 genes of 307 samples HFMD; sequencing the purified PCR products from 14 samples. Using ClustalW2 online analysis software for sequence and phylogenetic analysis of enterovirus 71. RESULT: Percentage of positive EV71 from different samples is shown as follows respectively: positive EV71 from stool samples is 24.4% (75/307), from throat swab--7.8% (24/307), from peripheral blood--12.5% (1/8). Percentage of positive CoxA16 is shown as follows respectively: positive EV71 from stool samples is 13.8% (28/203), from throat swab-11.0% (20/181). Among all the 307 samples, three are positive for both EV71 and CoxA16. EV71 and CoxA16 are not detected in the samples of cerebrospinal fluid.Comparative analysis of nucleotide sequences of EV71 with those of strains BrCr and 11 deposited in GenBank demonstrated numerous disparities from 8 samples, but residue 595 from 2 samples and residue 658 from 1 sample are variable. The phylogenetic analysis based on VP1 region demonstrates that strains from 2 samples has the nearest genetic relationship with anhui strains, the farthest with BrCr and SHH02-6, SHZH02-40, SHZH03-58 strains, also strains from other 12 samples have the farthest genetic relationship with them. The genotypes A, B and C were classified as proposed by Brown et al. (1999). The EV71 from 14 samples were the member of genotype C.
CONCLUSION: EV71 among the pathogen of HFMD in Shenzhen in 2008 was majority. These EV71 may belong to the same genegroup with Anhui predominant strains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20387478

Source DB:  PubMed          Journal:  Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi        ISSN: 1003-9279


  7 in total

1.  Replication kinetics of coxsackievirus A16 in human rhabdomyosarcoma cells.

Authors:  Jun Jin; Mingming Han; Lin Xu; Dong An; Wei Kong; Chunlai Jiang
Journal:  Virol Sin       Date:  2012-07-28       Impact factor: 4.327

2.  The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.

Authors:  Qunying Mao; Yiping Wang; Jie Shao; Zhifang Ying; Fan Gao; Xin Yao; Changgui Li; Qiang Ye; Miao Xu; Rongcheng Li; Fengcai Zhu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015-02-25       Impact factor: 3.452

Review 3.  Coxsackievirus A16: epidemiology, diagnosis, and vaccine.

Authors:  Qunying Mao; Yiping Wang; Xin Yao; Lianlian Bian; Xing Wu; Miao Xu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2013-11-14       Impact factor: 3.452

4.  Construction and characterization of an infectious clone of coxsackievirus A16.

Authors:  Fei Liu; Qingwei Liu; Yicun Cai; Qibin Leng; Zhong Huang
Journal:  Virol J       Date:  2011-12-13       Impact factor: 4.099

5.  Transcriptome analysis reveals dynamic changes in coxsackievirus A16 infected HEK 293T cells.

Authors:  Jun Jin; Rujiao Li; Chunlai Jiang; Ruosi Zhang; Xiaomeng Ge; Fang Liang; Xin Sheng; Wenwen Dai; Meili Chen; Jiayan Wu; Jingfa Xiao; Weiheng Su
Journal:  BMC Genomics       Date:  2017-01-25       Impact factor: 3.969

6.  Public health services in Shenzhen: a case study.

Authors:  D Zhang; J Mou; J Q Cheng; S M Griffiths
Journal:  Public Health       Date:  2011-01       Impact factor: 2.427

7.  Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum.

Authors:  Jun Jin; Hongxia Ma; Lin Xu; Dong An; Shiyang Sun; Xueyong Huang; Wei Kong; Chunlai Jiang
Journal:  J Virol Methods       Date:  2012-11-20       Impact factor: 2.014

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.